Phillips JD. Heme biosynthesis and the porphyrias. Mol Genet Metab. 2019;128(3):164–77.

Article  CAS  Google Scholar 

de Souza PVS, Badia BML, Farias IB, Pinto W, Oliveira ASB. Acute hepatic porphyria: pathophysiological basis of neuromuscular manifestations. Front Neurosci. 2021;15: 715523.

Article  Google Scholar 

Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013;36(5):849–57.

Article  Google Scholar 

Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142(6):439–50.

Article  Google Scholar 

Bissell DM, Wang B. Acute hepatic porphyria. J Clin Transl Hepatol. 2015;3(1):17–26.

Article  Google Scholar 

GIVLAARI (givosiran) injection, for subcutaneous use [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; 2021.

GIVLAARI - Summary of Product Characteristics. Amsterdam: Alnylam Netherlands B.V.; 2021.

Balwani M, Sardh E, Ventura P, Peiro PA, Rees DC, Stolzel U, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382(24):2289–301.

Article  CAS  Google Scholar 

Ventura P, Bonkovsky HL, Gouya L, Aguilera-Peiro P, Montgomery Bissell D, Stein PE, et al. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int. 2022;42(1):161–72.

Article  CAS  Google Scholar 

Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med. 2019;380(6):549–58.

Article  Google Scholar 

Agarwal S, Simon AR, Goel V, Habtemariam BA, Clausen VA, Kim JB, et al. Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria. Clin Pharmacol Ther. 2020;108(1):63–72.

Article  CAS  Google Scholar 

Li J, Liu J, Zhang X, Clausen V, Tran C, Arciprete M, et al. Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion of givosiran, the first approved n-acetylgalactosamine-conjugated RNA interference therapeutic. Drug Metab Dispos. 2021;49(7):572–80.

Article  Google Scholar 

Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958–61.

Article  CAS  Google Scholar 

McDougall R, Ramsden D, Agarwal S, Agarwal S, Aluri K, Arciprete M, et al. The nonclinical disposition and pharmacokinetic/pharmacodynamic properties of N-acetylgalactosamine-conjugated small interfering RNA are highly predictable and build confidence in translation to human. Drug Metab Dispos. 2022;50(6):781–97.

Article  CAS  Google Scholar 

Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17–20.

Article  CAS  Google Scholar 

US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing. Spring Hill, MD: CDER; 2020.

Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481–504.

Article  CAS  Google Scholar 

Vora JP, Burch A, Peters JR, Owens DR. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care. 1992;15(11):1484–93.

Article  CAS  Google Scholar 

Lazareth H, Poli A, Bignon Y, Mirmiran A, Rabant M, Cohen R, et al. Renal function decline with small interfering RNA silencing aminolevulinic acid synthase 1 (ALAS1). Kidney Int Rep. 2021;6(7):1904–11.

Article  Google Scholar 

Ricci A, Guida CC, Manzini P, Cuoghi C, Ventura P. Kidney involvement in acute hepatic porphyrias: Pathophysiology and diagnostic implications. Diagnostics (Basel). 2021;11(12):2324.

Article  CAS  Google Scholar